整理 | GLP1减重宝典内容团队 市场最近盯上的，正是礼来的口服GLP-1药物 orforglipron。更准确地说，它不是已经确定会在4月正式开卖，而是审批窗口已经逼近。 礼来自己的公开表述是，这款药针对肥胖或超重适应症的美国监管结果有望在2026年第二季度出炉，市场普遍关注的时间点集中在4月 上旬。礼来管理层同时表示，公司正按二季度上市的节奏做准备。 如果这张牌顺利落地，最先感到疼的，不会是整个司美格鲁肽市场同时被掀翻，而是口服司美格鲁肽先被正面撞上。礼来披露， orforglipron 是一款每日一次的小分子口服GLP-1，可以不受进食和饮水限制服用；相比之下，诺和诺德现有的 Rybelsus 和 Wegovy 片 剂都要求晨起空腹、以少量清水送服，并至少等待30分钟后才能进食、饮水或服用其他口服药。对真实世界依从性来说，这不是小差 别，而是会直接影响患者能不能长期坚持。 数据层面，礼来也已经把矛头直接对准了口服司美格鲁肽。在一项头对头Ⅲ期研究中，orforglipron 36 mg 在2型糖尿病患者中的糖化血 红蛋白降幅达到2.2%，口服司美格鲁肽14 mg为1.4%；体重降幅分别为9.2%和5.3 ...

Key Takeaways Novo Nordisk won FDA approval for Awiqli, a once-weekly basal insulin for adults with type II diabetes.Awiqli showed strong HbA1c reduction in the phase IIIa ONWARDS studies vs. daily basal insulin.NVO plans a U.S. launch of the FlexTouch device in the second half of 2026 after global approvals.Novo Nordisk (NVO) announced that the FDA has approved Awiqli injection as the first and only once-weekly, long-acting basal insulin icodec for adults with type II diabetes (T2D). The therapy is indicat ...

Over the past year, the two leaders in the obesity drug market, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), have lagged broader equities, though the latter has performed substantially worse than the former. Still, analysts predict that this therapeutic area will soar over the next decade, and there is a good chance these two will maintain their edge over their peers given their pipelines. But which one is a better buy? Comparing their weight loss portfolios Eli Lilly's weight loss medicine, Zepbou ...

  “The window to shape the oral GLP-1 market is open now….” Early-stage discussions with several multinational pharmaceutical companies currently underway   Kelowna, British Columbia – March 24, 2026 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms provides this update of developments within the glucagon-like peptide-1 (“GLP-1”) market. Lexaria has been listening and responding to the concerns of those using GLP-1 drugs, ...

大健康 | 2026 年 3 月 20 日 诺和诺德 | NVO US 静待价值重估 全球代谢龙头诺和诺德 (Novo Nordisk, NVO US) 的估值修复。公司正 处于一个独特的历史交汇点：股价在 2025 年经历回调，估值压缩，市场 忽视了公司在核心糖尿病领域的稳固份额及在全球肥胖市场的长期领先 统治力。短期催化剂有产能释放带来的业绩反弹，中期有 CagriSema 和口服新药的确证性数据，长期有 Amycretin 和新适应症拓展带来的第 二营收增长空间。这种由过渡期阵痛引发的抛售，与公司长期稳健的基 本面形成背离，创造具吸引力的入场点。 2026 年估值逻辑与股价回升。模型遵循管理层-5%至-13%的指引，假设 公司 2026 年调整后销售与营业利润将可能出现分别约 -6%及-9%的下 滑。而 13 倍的 2026 年预期市盈率 (P/E)反映了市场开始透过短期负增 长的迷雾，提前定价 2027 年的反弹。13 倍 P/E 对应的是公司作为 GLP- 1 龙头的溢价，以及对利空出尽的预期。一旦 340B 尘埃落定且重组完 成，优于-13%下限的表现可能成为惊喜。2025 年的回调主要受市场对产 ...

Core Insights - Novo Nordisk (NVO) shares have dropped 22% in the past month, resulting in a loss of nearly $50 billion in market capitalization due to disappointing clinical developments and rising pricing pressures [2] - Eli Lilly (LLY) has emerged as a significant competitor in the GLP-1 obesity market, with its therapy Zepbound (tirzepatide) outperforming NVO's Wegovy in clinical trials [3][4] - Novo Nordisk plans to cut U.S. list prices for Wegovy, Ozempic, and Rybelsus to $675 per month starting January 2027 to enhance patient access, which may compress margins amid increasing competition [7] Competitive Landscape - Eli Lilly's Zepbound achieved 25.5% weight loss in a phase III study, surpassing Novo Nordisk's CagriSema, which recorded 23% weight loss, marking a competitive setback for NVO [4][5] - Lilly's oral GLP-1 candidate, orforglipron, has also outperformed Novo Nordisk's Rybelsus in a phase III study for type II diabetes, further strengthening Lilly's position in the market [6] Financial Performance - Novo Nordisk's stock has underperformed, losing 29.1% over the past six months compared to the industry's 20% growth [19] - The company's shares currently trade at a price/earnings ratio of 11.59, significantly lower than the industry average of 17.90, indicating a discount in valuation [22] Growth Outlook - Novo Nordisk's growth outlook is deteriorating due to slowing demand, rising costs, and limited near-term catalysts, with earnings estimates for 2026 and 2027 declining [8][24] - The company is expanding its portfolio beyond GLP-1 treatments, seeking approvals for therapies in rare diseases and liver care, including treatments for hemophilia and metabolic dysfunction-associated liver disease [15][16] Pipeline Developments - Novo Nordisk is advancing several next-generation obesity candidates, including CagriSema and amycretin, to strengthen its competitive position in the obesity market [17][18] - The company has also entered partnerships to develop oral small-molecule medicines for obesity and diabetes, indicating a strategic focus on expanding its treatment options [18]

Core Viewpoint - The article discusses the recent developments and market dynamics surrounding Semaglutide, a drug by Novo Nordisk, particularly its new indication for treating metabolic-associated fatty liver disease (MASH) in China, highlighting its clinical efficacy and competitive landscape in the Chinese market [4][5][10]. Group 1: Drug Approval and Clinical Trials - Novo Nordisk submitted a new indication for Semaglutide in China for patients with moderate to severe liver fibrosis associated with MASH, aiming for priority review [4]. - Semaglutide received FDA approval in the U.S. in August 2025 for the same indication, requiring a low-calorie diet and increased physical activity [5]. - The ESSENCE clinical trial showed significant efficacy, with 36.8% of patients achieving liver fibrosis improvement without worsening fatty liver, compared to 22.4% in the placebo group [7]. Group 2: Sales Performance - In 2022, Semaglutide generated total sales of 228.29 billion Danish Krone (approximately 34.6 billion USD), accounting for 73.9% of Novo Nordisk's total revenue [9]. - The sales breakdown includes Ozempic (127.09 billion DKK, 19.27 billion USD, up 10%), Rybelsus (22.09 billion DKK, 3.35 billion USD, down 2%), and Wegovy (79.11 billion DKK, 11.99 billion USD, up 41%) [9]. Group 3: Market Competition and Future Outlook - The core sequence patent for Semaglutide in China will expire on March 20, 2026, leading to increased competition as multiple domestic versions are in the pipeline [10]. - Currently, 10 domestic Semaglutide products are under review, with 11 more in Phase III clinical trials, indicating a rapidly evolving market landscape [10]. - Novo Nordisk's ongoing expansion of Semaglutide's indications is expected to strengthen its position in weight loss, diabetes, and MASH treatment areas [11].

Core Insights - Novo Nordisk's shares fell 21% following disappointing clinical results and pricing pressures, erasing gains from the approval of Wegovy in 2021 [1] Competitive Landscape - Eli Lilly has become a significant competitor in the GLP-1 obesity market with its Zepbound, which has been gaining market share due to superior weight-loss efficacy compared to Wegovy [2] - In a recent phase III study, Zepbound achieved a 25.5% weight loss at 84 weeks, outperforming Novo Nordisk's CagriSema, which recorded a 23% weight loss, marking a competitive win for Lilly [3][4] - Eli Lilly's oral GLP-1 candidate, orforglipron, also outperformed Novo Nordisk's Rybelsus in a phase III study, achieving a 2.2% reduction in A1C and 9.2% weight loss at 52 weeks, indicating a stronger competitive position [5][6] Pricing Strategy - Novo Nordisk plans to reduce the U.S. list prices of its major products, including Wegovy, Ozempic, and Rybelsus, to $675 per month starting January 2027, aiming to improve patient access but risking margin compression amid rising competition [7] Market Performance - Novo Nordisk's stock has underperformed, losing 34% over the past six months compared to the industry's 24.5% growth [11] - The company's shares are trading at a forward P/E ratio of 11.17, significantly lower than the industry average of 18.70 and below its five-year mean of 29.25 [14] Earnings Estimates - Earnings estimates for Novo Nordisk have declined, with 2026 estimates dropping from $3.54 to $3.36 per share and 2027 estimates from $3.65 to $3.30 [16]

Core Viewpoint - RBC Capital initiated coverage of Eli Lilly (LLY) with an Outperform rating and a price target of $1,250, highlighting the company's potential to dominate the obesity market through 2030 [1] Group 1: Company Overview - Eli Lilly and Company (NYSE: LLY) is a pharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines for human health [3] Group 2: Market Position and Growth Potential - The obesity franchise of Eli Lilly is expected to lead the market, with investor sentiment remaining broadly positive despite some concerns over elevated expectations as the company approaches a $1 trillion market value [1] - Current consensus estimates are believed to materially undervalue Lilly's future growth potential, especially with transformative catalysts anticipated [1] Group 3: Product Performance - Eli Lilly's experimental weight-loss pill, orforglipron, demonstrated stronger effectiveness in controlling blood sugar and reducing weight compared to Novo Nordisk's Rybelsus, lowering blood sugar levels by 2.2% versus 1.4% and resulting in an average weight loss of 8.9 kg compared to 5 kg for Rybelsus [2] - However, orforglipron also had a higher incidence of side effects, with 58% of patients reporting mild-to-moderate side effects compared to 45% for Rybelsus, and a higher discontinuation rate due to side effects [1][2]

Core Insights - The global metabolic disease drug development sector is experiencing significant activity, highlighted by two major strategic partnerships involving Pfizer and Novo Nordisk, signaling a shift in the GLP-1 market dynamics [1][2][3] Group 1: Strategic Partnerships - Pfizer has secured exclusive commercialization rights for the GLP-1 receptor agonist, Enoglutide, in mainland China through a partnership with Hanzhou Xianweida Biotech, with a total deal value of up to $495 million [1][4] - Novo Nordisk has entered a $2.1 billion collaboration with Vivtex to develop next-generation oral medications for obesity and diabetes, aiming to overcome current delivery technology limitations [2][8] Group 2: Market Dynamics - The GLP-1 market is transitioning from a focus on efficacy to a more complex competition involving technology platforms and commercialization ecosystems [3][11] - The competitive landscape is shifting as local Chinese biotech firms begin to play a more significant role, with partnerships between multinational corporations and local companies becoming a prevalent strategy [10][13] Group 3: Company Strategies - Pfizer's recent strategy reflects a shift from self-research failures to aggressive business development, seeking to quickly fill gaps in its GLP-1 pipeline through partnerships [4][6] - Novo Nordisk's collaboration with Vivtex is seen as a defensive move to maintain its competitive edge in the oral medication space, especially in light of recent clinical trial results showing its current products lagging behind competitors [2][8] Group 4: Financial Implications - The financial stakes are high, with Novo Nordisk's revenue for 2025 reaching approximately $48.9 billion, driven largely by its GLP-1 products, while Eli Lilly's revenue reached $65.2 billion, showcasing the lucrative nature of the GLP-1 market [11][12] - The impending patent expirations and the influx of generic competitors are prompting significant price reductions in the GLP-1 market, indicating a shift towards more accessible pricing for these medications [12][13]